Shield Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Shield Therapeutics es Anders Lundstrom, nombrado en Jul 2024, tiene una permanencia de menos de un año. posee directamente un 0.001% de las acciones de la empresa, con un valor de £285.29. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 4 años, respectivamente.
Información clave
Anders Lundstrom
Chief Executive Officer (CEO)
US$53.5k
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.001% |
| Permanencia media de la dirección | 1.6yrs |
| Promedio de permanencia en la Junta Directiva | 4yrs |
Actualizaciones recientes de la dirección
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15CEO
Anders Lundstrom (62 yo)
less than a year
Permanencia
US$53,542
Compensación
Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | less than a year | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 16.8yrs | US$47.17k | 1.49% £ 332.1k | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| General Counsel & Company Secretary | 7.2yrs | sin datos | sin datos | |
| Group HR Director | no data | sin datos | sin datos | |
| Head of Pharmacovigilance & Medical Information | no data | sin datos | sin datos | |
| Chief Commercial Officer | 1.6yrs | sin datos | sin datos | |
| Senior Director of People & Culture | no data | sin datos | sin datos |
1.6yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de STX no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | 3.5yrs | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 4.4yrs | US$47.17k | 1.49% £ 332.1k | |
| Independent Non Executive Chairman | 6.3yrs | US$119.83k | 0.70% £ 156.7k | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 8.8yrs | US$76.49k | 0.023% £ 5.1k | |
| Notable Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 3.5yrs | US$47.17k | 0.035% £ 7.7k | |
| Notable Scientific Advisory Board | no data | sin datos | sin datos | |
| Notable Scientific Advisory Board | no data | sin datos | sin datos | |
| Notable Scientific Advisory Board | no data | sin datos | sin datos |
4.0yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de STX se considera experimentada (4 años de antigüedad promedio).